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Abstract: Previously, we described the link between C-X-C motif chemokine 12 (Cxcl12) gene induction 
and DNA hypomethylation in the absence of poly(ADP-ribose) polymerase 1 (PARP-1). We have now 
firmly established that demethylation is the primary cause of gene induction on the basis of Cxcl12 gene 
upregulation upon treatment with the demethylating agent 5-azacytidine (5-aza). Since the demethylation 
state of Cxcl12 is favored by PARP-1 absence, we investigated the presence of ten-eleven translocation 
(TET) proteins on the Cxcl12 promoter in order to corroborate the relationship between the demethylation 
process and increased gene expression that occurs in the absence of PARP-1. Analysis was performed on 
the promoter region within CpG islands of Cxcl12 from control mouse embryonic fibroblasts (NIH3T3) 
and PARP-1 knock-out mouse embryonic fibroblasts (PARP1-/-). The lack of PARP-1 increased the 
abundance of TET2 on the Cxcl12 promoter, suggesting that TET-mediated demethylation provoked by the 
absence of PARP-1 could account for the observed increased expression of this chemokine. Deciphering 
the regulation of DNA (de)methylation factors that control Cxcl12 expression may provide an additional 
therapeutic approach in pharmacological interventions where gene switching on or off based on targeted 
stimulation or inhibition is necessary. 
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INTRODUCTION 
DNA methylation is a covalent modification of genomic DNA that occurs predominantly at CG 
dinucleotides (CpG) where DNA methyltransferase (DNMTs) enzymes mediate the transfer of a 
methyl group to the 5-position of cytosines, generating 5-methylcytosine (5mC), which is assumed 
to be a fifth DNA base [1-3]. Ten-eleven translocation 1-3 (TET1-3) proteins, members of the 
DNA hydroxylase family, affect the methyl group on 5mC by catalyzing the consecutive oxidation 
of 5mC into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) [4,5]. Further, 5caC can be replaced by an unmethylated cytosine by thymine-DNA 
glycosylase (TDG) via the base excision repair (BER) pathway [6]. Hence TET proteins can 
generate both new epigenetic marks (5hmC, 5fC and 5caC) in genomic DNA and also reverse the 
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5mC to the unmethylated state which comprises the process of active DNA demethylation [7,8]. 
Since DNA (de)methylation is closely linked to gene expression, it is important to explore the 
regulation of these mechanisms when related to various diseases which are characterized by 
aberrant DNA methylation. Poly(ADP-ribose)polymerase (PARP) enzymes, which catalyze 
covalent attachment of poly-ADP-ribose (PAR) units to acceptor proteins (PARylation), take part 
in the regulation of DNA (de)methylation processes [9]. PARP-1 is the founding member of PARP 
family that participates in the production of PAR polymers. Besides PARP-1 automodification 
where the enzyme PARylates itself, it can also PARylate covalently other target proteins, thereby 
modulating their activities and functions. PAR moieties can also bind non-covalently to target 
proteins that expand the number of PARP-1 interacting partners subjected to PARylation [9-11]. 
The link between PARP-1 and TET activity in DNA demethylation is emerging as a newly 
discovered role of PARP-1 [11]. 
In our previous study we reported that PARP-1 promotes DNA methylation and the opposite, 
that lack of PARP-1 is connected with the demethylation state of Cxcl12 gene; this also 
corresponds with changes in Cxcl12 expression, which tends to increase in the absence of PARP-
1 [12]. CXCL12, also known as stromal cell-derived factor 1 (SDF-1), is a potent CXC chemokine 
produced by different cell types. It is involved in the migration of a variety of cells, including 
hematopoietic progenitor and stem cells, endothelial cells and most leukocytes [13]. CXCL12 is 
involved in physiological and pathological processes, such as development, cell survival, tissue 
repair and regeneration, as well as cancer [14,15]. The methylation status of the Cxcl12 gene plays 
an important role in tumor progression in human carcinogenesis. For example, epigenetically-
controlled downregulation of the Cxcl12 by promoter hypermethylation has been detected in breast 
tumors [16] and in osteosarcomas [17], and is connected with metastatic potential and poor 
survival prognosis. Hence, the methylation status of Cxcl12 could be used as a target for 
therapeutic interventions. 
Since we previously found PARP-1 to be a potential upstream player in methylation events 
that modulated Cxcl12 expression, our aim was to examine whether a lack of PARP-1 would 
induce TET enzymes to demethylate Cxcl12. 
 
MATERIALS AND METHODS 
Cell culture and treatment 
The following cell lines were used: mouse embryonic fibroblasts, NIH3T3 (ATCC- CRL-1658), 
and PARP-1 knock-out (PARP1-/-) cells [18]. The cells were cultured in high glucose Dulbecco’s 
Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), L-
glutamine and penicillin/streptomycin (all cell culture reagents were supplied by Biological 
Industries, Beit Haemek Ltd., Israel). NIH3T3 cells were treated with 15 µM 5-azacytidine (5-aza) 
solubilized in dimethyl sulfoxide (DMSO) for 72 h, with the treatment replaced every 24 h. In 
parallel with the 5-aza treatment, control NIH3T3 cells were treated with DMSO in the same 
manner. 
RNA isolation, reverse transcription and real-time quantitative PCR (RT-qPCR) 
Total RNA was isolated from NIH3T3 cells treated with 5-aza or DMSO and PARP1-/- cells using 
the GeneJET RNA Purification Kit (Thermo Fisher Scientific, USA). Reverse transcription was 
performed on 1 µg of DNase I-treated RNA by the RevertAid First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific, USA) with a mix of oligo(dT)18 and random hexamer primers. For RT-
qPCR we used QuantStudio 3 Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) 
and Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher Scientific, USA). The thermal 
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cycles were as follows: initial denaturation at 95°C for 10 min and 40 cycles of two-step PCR at 
95°C for 15 s and at 60°C for 60 s. Expression of Cxcl12 was estimated relative to GAPDH (as an 
internal control) by the delta Ct method (2dCt) with previously published primers [12] 
(Supplementary Table S1). The obtained data was log2 transformed for statistical testing and 
statistical significance was estimated using ANOVA with Dunnett’s post-hoc test used to compare 
NIH3T3 5-aza-treated and PARP-/- cells with control NIH3T3 cells mock-treated with DMSO. 
For graphs, mean values and error bars were transformed back to the linear scale. 
DNA isolation, bisulfite conversion and methylation-specific PCR (MSP) 
To isolate high molecular weight DNA we used cell lysis buffer (2 mM EDTA, 10 mM Tris-HCl 
pH 7.5, 10 mM NaCl, 0.5% sodium dodecyl sulfate (SDS)) supplemented with 0.04 µg/mL 
proteinase K. After overnight incubation at 55°C, the lysates were ethanol-precipitated with cold 
75 mM sodium acetate diluted in absolute ethanol. The isolated high molecular weight DNA was 
resuspended in water. 
The EZ-DNA methylation kit (D5002; Zymo Research, Orange, CA, USA) was used for 
bisulfite conversion of genomic DNA, as per the provided instructions. This bisulfite-converted 
DNA served as a template for MSP analysis of DNA methylation changes. The promoter (1MU), 
the exon-intron boundary (2MU) and part of the intron (3MU) of Cxcl12 were analyzed (Fig. 2) 
with three sets of MSP primers (Supplementary Table S1) that were previously published [12]. 
Each set was comprised of two pairs of primers targeted to the same location yet differentiating 
between the methylation states, as one pair was complementary to the methylated (M) and the 
other to the unmethylated (U) bisulfite-converted target DNA sequence. Separate reactions were 
set up for each primer pair, ensuring that reactions for one sample with primers from the same set 
were always run in parallel, within the same PCR run. Each reaction had a volume of 10 µL and 
contained 2 µM primers, 60 ng of bisulfite-converted DNA and Maxima SYBR Green/ROX qPCR 
Master Mix (Thermo Fisher Scientific, USA). The QuantStudio 3 Real-Time PCR system (Applied 
Biosystems, Carlsbad, CA, USA) was used for the runs with the following temperature cycling 
profile: initial denaturation at 95°C for 10 min and 40 cycles of two-step PCR at 95°C for 15 s and 
58°C for 60 s. Finally, to assess the relative level of methylation, threshold cycle values (Ct) for 
M and U primer pairs from the same set were used to calculate the methylation index [19] using 
the following equation: 
2(Ct for U primer pair reaction)-(Ct for M primer pair reaction). 
The obtained data was log2 transformed for statistical testing and statistical significance was 
estimated using ANOVA with Dunnett’s post-hoc test to compare the NIH3T3 5-aza-treated and 
PARP-/- cells with control NIH3T3 cells mock-treated with DMSO. For graphs, mean values and 
error bars were transformed back to the linear scale. 
Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was performed using the Pierce™ Magnetic ChIP Kit (Thermo 
Fisher Scientific, USA) according to the protocol. In brief, NIH3T3 and PARP-/- chromatin were 
cross-linked with 1% formaldehyde (Zorka Pharma, Serbia) and the process was stopped with a 
glycine solution after 10 min at room temperature. After extraction, the chromatin was digested 
with 0.005 U/µL micrococcal nuclease and sheared on ice by sonication (7 rounds of 20 s 
sonication and 30 s rest). Immunoprecipitation was performed using Protein A/G Magnetic Beads 
(USA) and the following antibodies: anti-RNA polymerase II (RNA pol II) (supplied with the 
ChIP kit), normal rabbit IgG (supplied with the ChIP kit), 5 µg of anti-TET1 (Millipore Merck, 
USA) and 5 µg of anti-TET2 (Millipore Merck, USA). The cross-linking was reversed at 65°C 
and the immunoprecipitated samples and samples containing 10% of total input were treated with 
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40 µg proteinase at 65°C for 1.5 h. The abundance of the target sequence was assessed by 
quantitative PCR (qPCR) using QuantStudio 3 Real-Time PCR system (Applied Biosystems, 
Carlsbad, CA, USA) and Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher 
Scientific, USA). Primers (Supplementary Table S1) were designed to amplify part of the promotor 
region directly adjacent to the transcription start site (TSS) of Cxcl12 (Fig. 2). To quantify the 
enrichment, first the quantity of ChIP and IgG samples was determined from a standard curve 
generated with qPCR data of 10-fold dilution series of the 10% total input samples. Enrichment 
was calculated by normalizing to IgG sample quantity and fold enrichment was reported relative 
to the corresponding NIH3T3 samples (immunoprecipitated by the same antibody) from the same 
experiment. The experiment was repeated twice. 
Co-immunoprecipitation (IP) 
NIH3T3 and PARP-/- cells were lysed in ice-cold ProteoJET™ Mammalian Cell Lysis Reagent 
(Thermo Fisher Scientific, USA), supplemented with a protease inhibitor cocktail, for 30 min at 
4°C. Cell lysates (300 µg) were precleared by incubation with Protein A/G agarose-coupled beads 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The precleared lysate was incubated overnight 
at 4°C on a tube rotator with 2 µg of anti-TET2 antibody (Millipore Merck, USA), which was 
followed by the addition of protein A/G agarose-coupled beads (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and further incubation at 4°C for 4 h. The agarose beads were pelleted and washed 
5 times with a buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.2 
mM phenyl methyl sulfonyl fluoride (PMSF) and a protease inhibitor cocktail. Proteins were 
eluted from the beads by boiling in a sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% 
glycerol, 100 mM dithiothreitol, 0.02% bromophenol blue), separated by 7% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) alongside 70 µg of proteins from the 
NIH3T3 lysate. The proteins were electrotransferred onto polyvinylidene difluoride (PVDF) 
membranes and analyzed by immunoblotting. 
Immunoblot analysis 
NIH3T3 and PARP-/- cells were lysed in ice-cold RIPA buffer (Sigma Aldrich, USA) 
supplemented with a protease inhibitor cocktail for 30 min at 4°C. Equal amounts of cell lysates 
were separated by 12% SDS-PAGE and electrotransferred onto PVDF membranes. 
Immunoblotting for lysates or IP samples was performed by overnight incubation at 4°C with anti-
PARP-1 (H-250, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-TET2 primary 
antibodies (Millipore Merck, USA) and anti-GAPDH (FL-335, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) as loading control for lysates. This was followed by incubation with horseradish 
peroxidase‐conjugated anti‐rabbit secondary antibody at room temperature for 1 h. Staining was 
performed by the enhanced chemiluminescence detection system (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) according to the manufacturer's instructions. 
 
RESULTS 
Cxcl12 expression was increased in 5-aza-treated NIH3T3 and PARP-/- cells 
Treatment of NIH3T3 cells with the demethylating agent 5-aza induced a higher level of Cxcl12 
expression as measured by real-time PCR. Treated NIH3T3 cells showed on average a 5.5-fold 
increase compared to control NIH3T3 cells, while PARP-/- cells showed an even greater increase 
of 2x105-fold compared to the control (Fig. 1). Both observed increases were statistically 
significant (p5aza=0.02 and pPARP-/-=1.9x10-8). 
Methylation changes of Cxcl12 in 5-aza-treated NIH3T3 and PARP-/- cells 
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As previously established [12], murine Cxcl12 gene has a CpG island that spans a part of its 
promoter, first exon and part of the first intron (Fig. 2). The methylation changes of Cxcl12 on 
these regions were examined as follows: amplicons analyzed by MSP covered 8 CpGs in the 
promoter, 23 CpGs at the exon-intron boundary and 8 CpGs in the intron region. In accordance 
with the changes in expression, we observed that both the treatment of NIH3T3 cells with 5-aza 
and the absence of PARP-1 resulted in demethylation of Cxcl12. Cells treated with 5-aza exhibited 
a statistically significant decrease in methylation, on average 45.4-fold in the promoter region 
(p=1x10-6) and 4.3-fold at the exon-intron boundary (p=3.9x10-4), while the intron region was not 
significantly affected (Fig. 3). PARP-/- cells showed a significantly higher level of demethylation 
(Fig. 3). Compared to NIH3T3 cells, methylation in PARP-/- cells was decreased 1032.4-fold in 
the promoter (p=3.6x10-8), 1002.4-fold in the exon-intron boundary (p=3.1x10-8) and even 285.3-
fold in the intron region (p=5.2x10-8). 
The level of TET2 at the Cxcl12 promoter is higher in the absence of PARP-1 
ChIP analysis showed that TET proteins interact with the Cxcl12 promoter. Control ChIP 
experiments performed with an anti- RNA pol II antibody confirmed that RNA pol II was more 
abundantly present (on average 5.7-fold more) on the Cxcl12 promoter of PARP-/- than of NIH3T3 
cells (Fig. 4). This result was in agreement with the Cxcl12 expression profile in these cells. The 
results for TET1 were deemed inconclusive as no consistent change was observed (data not 
shown). We therefore focused on TET2, as it was consistently present in higher abundance (on 
average 1.32-fold) on the analyzed region of the Cxcl12 promoter in PARP-/- when compared to 
NIH3T3 cells (Fig. 4). 
TET2 interacts with PARP-1 
Western-blot analysis confirmed the absence of PARP-1 in PARP-/- cells and showed higher levels 
of TET2 isoforms (223 kDa and 130 kDa) in PARP-/- as compared to NIH3T3 cells (Fig. 5A). 
Results of IP analysis showed that TET2 was successfully immunoprecipitated from NIH3T3 cell 
lysates and that it co-precipitated PARP-1, confirming their interaction in cellulo (Fig. 5B). 
 
DISCUSSION 
In the past decade, much attention has been focused on the role of epigenetic alterations in cancer 
progression [20]. The increased metastatic potential in some types of cancers, such as colon, 
mammary and breast carcinomas, was shown to be associated with epigenetic silencing of Cxcl12 
[16,21,22]. Furthermore, considering the ability of CXCL12 to stimulate the growth and survival 
of pancreatic β-cells, the transcriptional regulation of this chemokine could provide an approach 
for diabetes treatment [23]. Hence, therapies that target CXCL12 expression via de/methylation 
possess the potential for therapeutic interventions, and identification of factors that affect the 
methylation status of this chemokine is of great importance. 
In this study we verified that PARP-1 affected the methylation status of Cxcl12 whereby the 
absence of PARP-1 promoted TET2 involvement on the Cxcl12 promoter, linking TET-dependent 
demethylation and increased gene expression in the absence of PARP-1. Restored expression of 
Cxcl12 after treatment with 5-aza, one of the most frequently used demethylating agents that 
inhibits DNMTs [24,25], confirmed the epigenetic transcriptional silencing of Cxcl12. While 
treatment with 5-aza is presumably based on inactivation of methylation due to rapid loss of 
DNMT activity, our previous results indicated that in PARP-/- cells the promotion of TET-
dependent active demethylation occurs rather than DNMT-related suppressed methylation [12]. 
We assumed that this scenario also occurs in the Cxcl12 gene; however, a direct link between TET-
mediated DNA demethylation and the transcriptional output is difficult to establish because of the 
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existence of global and locus-specific effects that are difficult to discern [26]. Demethylation of 
the Cxcl12 promoter region was expected as it was already established that the Cxcl12 gene is 
exposed to epigenetic regulation by methylation of cytosine in CpG dinucleotides located in the 
promoter sequence [27-29]. In the intron region there was no statistically significant decrease in 
methylation in NIH3T3 cells treated with 5-aza, whereas a significant decrease was observed in 
PARP-/- cells. This points to the stronger potential for demethylation of Cxcl12 in PARP-/- 
compared to NIH3T3 cells treated with 5-aza, which could have also contributed to the higher 
increase in Cxcl12 expression. 
Although the absence of PARP-1 in the demethylation event is clear, it remains to be 
elucidated whether the TETs are responsible for the loss of methylation. Our previous results 
suggested that PARP-1 could be involved in demethylation as significant increases in both TET1 
and TET2 expression were detected in the absence of PARP-1 [12]; herein we showed that the 
lack of PARP-1 increased TET2 occupancy on the Cxcl12 promoter. Furthermore, according to 
the obtained result there was no clear increase in TET1 on the Cxcl12 promoter (result not shown); 
however, this does not rule out the possibility that TET1 was also affected by the absence of PARP-
1 for recruitment and demethylation events on the Cxcl12 promoter. This assumption needs further 
validation. 
TET proteins preferentially bind to DNA containing unmodified cytosine [30-32]. While 
TET1 is recruited to genomic target sites through direct binding of CXXC domains to CpG-rich 
oligonucleotides [3,33,34], TET2 lacks the CXXC DNA-binding domain, thus it is more likely 
that its recruitment on a specific gene is mediated by interactions with other DNA-binding factors 
[35]. It was found that TET2 interacts with IDAX protein whose CXXC domain binds to 
unmethylated CpG dinucleotides in the promoter but in a sequence-nonspecific manner [31]. A 
very recent report described the mechanism for targeting TET2 to specific promoters [36]. It was 
proposed that transcriptional co-activator SMAD nuclear interacting protein 1 (SNIP1) bridges 
TET2 to bind to a sequence-specific DNA-binding factor c-MYC, thus facilitating the recruitment 
of TET2 to regulate c-MYC target genes by promoting DNA demethylation at the promoters [36]. 
In addition, it is well established that the posttranslational modification, monoubiquitylation, 
which is catalyzed by CRL4VprBP E3 ligase, promotes the DNA binding of TET2 by stabilizing 
the conformation of TET2 complexed with DNA (where the monoubiquitylation site directly 
contacts the DNA) [32,37]. 
The activity of TETs can be modulated by metabolites, cofactors and several post-
translational modifications [35]. Our previous results marked TETs as potentially important factors 
in Cxcl12 expression in the absence of PARP-1. This was supported by the detected tendency of 
Cxcl12 expression to increase in the presence of TET activators (vitamin C), and to decrease upon 
treatment with the TET inhibitor dimethyloxaloylglycine (DMOG) in PARP-/- cells [12]. The 
findings presented herein encourage us to assume that the lack of PARP-1 was responsible for the 
increased recruitment of TET2 to the Cxcl12 promoter, which is a prerequisite step that leads to 
augmented activity and demethylation events. 
As interactions between TET2 and PARP-1 in human embryonic kidney 293T (HEK293T) 
cells were reported [38], it was expected that these proteins establish interactions in NIH3T3 cells, 
as we have showed. We assumed that these interactions could have an inhibitory role on the 
catalytic activity of TETs, since our previous results showed a global increase in TET 
expression/activity in the absence of PARP-1 [12]. Hence the catalytic activation of TET enzymes 
together with the increased recruitment of TET2 in the absence of PARP-1 could have contributed 
to the local demethylation event on the Cxcl12 promoter, accounting for its induced expression. 
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This is in collision with some literature data showing that inhibition of PARylation suppresses the 
production of 5hmC by TET proteins and consequently region-specific demethylation [39]. 
Nevertheless, the role of PARP-1 in demethylation and its impact on TET activity was recently 
reviewed and it was pointed out that data implicating PARP/TET interplay in the regulation of 
(de)methylation that can produce opposite effects, resulting in either increased or decreased 5mC-
hydroxylase activity, is still emerging [11]. Consistent with this view is the observation that after 
inhibition of PARylation, aside from a number of hypermethylated genes, several genes were also 
found to be hypomethylated [40]. 
 
CONCLUSION 
Enrichment of the Cxcl12 promoter with TET2, together with the previously described overall 
increased expression and activity of TETs in the absence of PARP-1, highlight the connection of 
PARP-1 and gene expression through (de)methylation events, and support the inhibitory role of 
PARP-1 in demethylation, which explains the increased expression of Cxcl12. Future research 
should focus on exploring the effect of PARP activity (not only its presence) on Cxcl12 expression 
and on epigenetic events as this could enhance the efficacy of PARP inhibitors in their potential 
clinical translation. 
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Figure Legends 
 
Fig. 1. Relative expression level of Cxcl12 in control NIH3T3 cells (mock-treated with DMSO), 
NIH3T3 cells treated with 15 µM 5-aza and PARP−/− cells (n = 5) measured by RT-qPCR. 
Statistical significance is reported for the comparison of NIH3T3 5-aza-treated and PARP-/- cells 
to the control NIH3T3 cells. Results are presented as the mean±standard error of the mean, 
*p≤0.05, ***p ≤ 0.001, n‐number of independent experiments. 
 
Fig. 2. Schematic representation of murine Cxcl12 and positions of primers used for MSP and 
ChIP qPCR. 
 
Fig. 3. Methylation levels of different parts of Cxcl12 of control NIH3T3 cells (mock-treated with 
DMSO), NIH3T3 cells treated with 15 µM 5-aza and PARP−/− cells measured by methylation‐
specific PCR (MSP) (n = 4). Under each graph, the amplicon sequence is represented with 
highlighted CG dinucleotides. Statistical significance is reported for the comparison of NIH3T3 
5-aza-treated and PARP-/- cells to the control NIH3T3 cells. Results are presented as the 
mean±standard error of the mean, *p≤0.05, ***p≤0.001, n‐number of independent experiments. 
 
Fig. 4. ChIP-qPCR analysis of RNA pol II and TET2 occupancy at the Cxcl12 promoter in NIH3T3 
and PARP-/- cell lines (n=2). Results are presented as the mean±standard error of the mean. 
 
Fig. 5. A – Immunoblot analysis performed with anti-TET2, anti-PARP-1 and anti-GAPDH 
(loading control) antibodies, on lysates isolated from NIH3T3 and PARP-/- cell lines. B - 
Immunoprecipitation of TET2 from NIH3T3 cells analyzed by immunoblotting with anti-TET2 
and anti-PARP-1. Successful immunoprecipitation of TET2 was confirmed as well as 
coprecipitation of PARP-1 with TET2. IP – immunoprecipitation. 
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